Product
AOC 1001
3 clinical trials
21 indications
Indication
DM1Indication
Myotonic Dystrophy 1Indication
Myotonic DystrophyIndication
Myotonic Dystrophy Type 1 (DM1)Indication
Myotonic DisordersIndication
Steinert DiseaseIndication
Myotonic Muscular DystrophyIndication
Genetic DiseasesIndication
InbornIndication
Heredodegenerative DisordersIndication
Nervous SystemIndication
Neurodegenerative DiseasesIndication
Muscular DystrophyIndication
Muscular DisordersIndication
AtrophicIndication
Muscular DiseasesIndication
Musculoskeletal DisordersIndication
Neuromuscular DisordersIndication
Nervous System DiseasesIndication
MyotoniaIndication
SteinertClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple-Doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) PatientsStatus: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) PatientsStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1Status: Not yet recruiting, Estimated PCD: 2026-10-01